Literature DB >> 26860334

Community correctional agents' views of medication-assisted treatment: Examining their influence on treatment referrals and community supervision practices.

Shannon Gwin Mitchell1, Jennifer Willet2, Laura B Monico1, Amy James2, Danielle S Rudes3, Jill Viglione4, Robert P Schwartz1, Michael S Gordon1, Peter D Friedmann5,6,7.   

Abstract

BACKGROUND: Alcohol and opioid use disorders are common among adults under community supervision. Although several medications (medication-assisted treatment or MAT) are Food and Drug Administration (FDA)-approved to treat such disorders, they are underutilized with this population despite established effectiveness at decreasing substance use. This paper examines how community correctional agents' understanding of addiction and views of MAT influence their professional actions regarding addiction medications.
METHODS: A total of 118 semistructured qualitative interviews were conducted with community correctional agents taking part in the CJ-DATS MATICCE implementation study across 20 parole/probation offices in 9 US states. Using grounded theory methodology and an iterative analytic approach, issues of role perception, views of MAT, current treatment referral, and community supervision practices were explored.
RESULTS: Agents often had limited autonomy to make direct treatment referrals, regardless of their views of MAT, as they were required to follow court orders and their organization's policies and procedures. Within some organizations, community correctional agents held sufficient autonomy to make direct treatment referrals, with agents struggling to reconcile their desire to support their clients who needed MAT with concerns about the abuse potential of opioid agonist medications. Viewing MAT as a "treatment of last resort" was counterbalanced by the view that it was an effective evidence-based practice. Agents described how MAT impacted their ability to supervise clients and how their knowledge and understanding of MAT was directly influenced by watching their clients who were successful or unsuccessful on MAT. Even those agents who were more accepting of MAT were largely unsupportive of it long-term use.
CONCLUSIONS: Community correctional agents' views of MAT were influenced by their understanding of addiction as well as their experiences supervising clients receiving treatment with medications, but whether or not MAT referrals were made was not always within their control.

Entities:  

Keywords:  Buprenoprhine; implementation; medication-assisted treatment; methadone; parole; probation

Mesh:

Substances:

Year:  2016        PMID: 26860334      PMCID: PMC4823810          DOI: 10.1080/08897077.2015.1129389

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  20 in total

1.  Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.

Authors:  Shannon Gwin Mitchell; Jan Gryczynski; Sharon M Kelly; Kevin E O'Grady; Jerome H Jaffe; Yngvild K Olsen; Robert P Schwartz
Journal:  J Drug Issues       Date:  2014-01

2.  Opioid pharmacotherapy in criminal justice settings: now is the time.

Authors:  Joshua D Lee; Josiah D Rich
Journal:  Subst Abus       Date:  2012       Impact factor: 3.716

3.  WHO status paper on prisons, drugs and harm reduction.

Authors: 
Journal:  Euro Surveill       Date:  2005-07-14

4.  Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime.

Authors:  Jan Gryczynski; Timothy W Kinlock; Sharon M Kelly; Kevin E O'Grady; Michael S Gordon; Robert P Schwartz
Journal:  Subst Abus       Date:  2012       Impact factor: 3.716

5.  Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections.

Authors:  Peter D Friedmann; Donna Wilson; Hannah K Knudsen; Lori J Ducharme; Wayne N Welsh; Linda Frisman; Kevin Knight; Hsiu-Ju Lin; Amy James; Carmen E Albizu-Garcia; Jennifer Pankow; Elizabeth A Hall; Terry F Urbine; Sami Abdel-Salam; Jamieson L Duvall; Frank J Vocci
Journal:  J Subst Abuse Treat       Date:  2014-10-14

Review 6.  Cocaine use by clients in methadone programs: significance, scope, and behavioral interventions.

Authors:  W S Condelli; J A Fairbank; M L Dennis; J V Rachal
Journal:  J Subst Abuse Treat       Date:  1991

7.  Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study.

Authors:  Marina Davoli; Anna M Bargagli; Carlo A Perucci; Patrizia Schifano; Valeria Belleudi; Matthew Hickman; Giuseppe Salamina; Roberto Diecidue; Federica Vigna-Taglianti; Fabrizio Faggiano
Journal:  Addiction       Date:  2007-12       Impact factor: 6.526

Review 8.  Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction.

Authors: 
Journal:  JAMA       Date:  1998-12-09       Impact factor: 56.272

Review 9.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

10.  Buprenorphine Treatment for Probationers and Parolees.

Authors:  Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Kathryn A Couvillion; Laura J Sudec; Kevin E O'Grady; Frank J Vocci; Hamin Shabazz
Journal:  Subst Abus       Date:  2014-04-04       Impact factor: 3.716

View more
  18 in total

1.  Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).

Authors:  Kenneth Blum; Marcelo Febo; Lyle Fried; Mona Li; Kristina Dushaj; Eric R Braverman; Thomas McLaughlin; Bruce Steinberg; Rajendra D Badgaiyan
Journal:  Subst Use Misuse       Date:  2016-12-29       Impact factor: 2.164

2.  Self-Help Groups And Medication Use In Opioid Addiction Treatment: A National Analysis.

Authors:  Hefei Wen; Benjamin G Druss; Brendan Saloner
Journal:  Health Aff (Millwood)       Date:  2020-05       Impact factor: 6.301

Review 3.  Update on Barriers to Pharmacotherapy for Opioid Use Disorders.

Authors:  Anjalee Sharma; Sharon M Kelly; Shannon Gwin Mitchell; Jan Gryczynski; Kevin E O'Grady; Robert P Schwartz
Journal:  Curr Psychiatry Rep       Date:  2017-06       Impact factor: 5.285

4.  Pharmacotherapy for opioid addiction in community corrections.

Authors:  Robert P Schwartz; Mary M Mitchell; Kevin E O'Grady; Sharon M Kelly; Jan Gryczynski; Shannon Gwin Mitchell; Michael S Gordon; Jerome H Jaffe
Journal:  Int Rev Psychiatry       Date:  2018-12-06

5.  State criminal justice policy context and opioid agonist treatment delivery among opioid treatment admissions, 2015.

Authors:  Shivani Mantha; Pia M Mauro; Christine M Mauro; Silvia S Martins
Journal:  Drug Alcohol Depend       Date:  2019-11-02       Impact factor: 4.492

6.  An Exploration of Practitioners' Perceptions and Beliefs About Trauma-Informed Youth Drug Prevention Programs: a Qualitative Study.

Authors:  Sunny H Shin; Leah M Bouchard; Benjamin Montemayor
Journal:  Prev Sci       Date:  2021-10-29

7.  The impact of the opioid crisis on U.S. state prison systems.

Authors:  Christy K Scott; Michael L Dennis; Christine E Grella; Allison F Mischel; John Carnevale
Journal:  Health Justice       Date:  2021-07-24

8.  Factors associated with interest in receiving prison-based methadone maintenance therapy in Malaysia.

Authors:  Trena I Mukherjee; Jeffrey A Wickersham; Mayur M Desai; Veena Pillai; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2016-05-09       Impact factor: 4.492

9.  A scoping review of factors that influence opioid overdose prevention for justice-involved populations.

Authors:  Christine E Grella; Erika Ostlie; Christy K Scott; Michael L Dennis; John Carnevale; Dennis P Watson
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-02-22

10.  Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder.

Authors:  Barbara Andraka-Christou; M H Clark; Danielle N Atkins; Brandon Del Pozo
Journal:  Subst Abus       Date:  2021-07-08       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.